## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 159.25 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential**
- Source: GuruFocus | 20251209T170905 | Bullish | Relevance: 99%
- Wedbush has initiated coverage on Sarepta Therapeutics (SRPT) with an Outperform rating, setting a price target of $32, which suggests a 46% upside potential. This optimistic outlook is based on the anticipated FDA re-approval of its drug Elevidys for non-ambulatory patients by early 2027. Despite strong revenue growth and liquidity, the company faces challenges with negative profitability and financial instability indicated by a low Altman Z-Score, positioning it as a speculative growth stock.

**2. Sarepta Therapeutics stock falls after debt exchange announcement**
- Source: Investing.com | 20251211T151006 | Neutral | Relevance: 99%
-  Sarepta Therapeutics stock dropped 3.7% after the company announced a debt exchange agreement. This deal involves restructuring approximately $291.4 million of its 1.25% convertible senior notes due 2027 into new 4.875% convertible senior notes due 2030, plus a cash component. The transaction is expected to finalize on December 18th.

**3. Norges Bank Buys Shares of 913,407 Sarepta Therapeutics, Inc. $SRPT**
- Source: MarketBeat | 20251209T110905 | Neutral | Relevance: 99%
-  Norges Bank has acquired a new position of 913,407 shares in Sarepta Therapeutics, valued at approximately $15.62 million, representing about 0.93% of the company. Institutional investors collectively own roughly 86.68% of SRPT. Despite a consensus "Hold" rating from analysts and a missed EPS target in the latest quarter, the company's revenue exceeded expectations.

**4. Sarepta Therapeutics Gets A Vote Of Confidence After Sell-Off**
- Source: Finimize | 20251209T170905 | Bullish | Relevance: 99%
-  Sarepta Therapeutics saw its shares rise after Wedbush issued an 'outperform' rating and a $32 price target, deeming the recent sell-off an overreaction. Despite setbacks with its gene therapy Elevidys, Wedbush sees recovery potential, citing strong sales from existing treatments and potential regulatory expansion. The biotech's resilience and the market's reaction highlight the unpredictable nature of innovation in the industry.

**5. Sarepta a new outperform at Wedbush as selloff overdone**
- Source: Seeking Alpha | 20251209T160905 | Bullish | Relevance: 98%
- Wedbush initiated coverage on Sarepta Therapeutics (SRPT) with an Outperform rating. The firm believes the selloff, which occurred earlier this year following the deaths of two boys on one of its Duchenne muscular dystrophy gene therapies, is overdone. Wedbush has set a $32 price target for SRPT.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 106.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Tudor Investment Cor: 65.7% (+135261.8%)
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (21.6%, 3.4 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 37.1% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 21.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.5 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 6.7% to 0.1% (-6.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 (-1.4%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.63x), long-term trend not supportive. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.09% (CS: 40) | Neutral |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | 0.34 | Bullish |
| vs SMA20 | 1.093x | Above |
| vs SMA50 | 1.037x | Above |
| vs SMA200 | 0.629x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $21.75
- **Stop Loss:** $18.93 (13.0% risk)
- **Target:** $24.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 489
- **Position Value:** $10,635.75
- **Portfolio %:** 10.64%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*